Literature DB >> 15172152

Multinational assessment of some operational costs of teletherapy.

Piet-Hein Van Der Giessen1, Jose Alert, Cholid Badri, Matija Bistrovic, Deepak Deshpande, Dimitris Kardamakis, Debbie Van Der Merwe, Neiro Da Motta, Luis Pinillos, Rena Sajjad, Ye Tian, Vic Levin.   

Abstract

BACKGROUND AND
PURPOSE: Decisions in planning radiotherapy facilities in countries with limited financial resources require information on economic factors to make provision for sustainability. This study aims at acquiring data on some of these factors involved in delivery of teletherapy in 11 countries of different economic status. PATIENTS AND METHODS: Representatives of three European, one African, three Latin American and four Asian countries, were identified from radiation oncology institutions that operated both cobalt and linac teletherapy machines. Productivity data were prospectively collected for the year 2002. A detailed log was recorded for each machine over an arbitrary two-week period. Data on quality assurance (QA), maintenance, the capital costs of each machine, and the source replacement costs for the cobalt units were also recorded.
RESULTS: Both linear accelerators and cobalt machines treat more than 10,000 fractions per year per machine with 2.5 and 2.3 fields per fraction, respectively. The capital costs of the machines vary considerably, with a factor of more than 10 for linear accelerators. Cobalt sources show a huge variation in price. The median costs of QA and maintenance of a linac was US$ 41,000 compared to US$ 6000 for cobalt machines. This results for the economic factors considered in median costs per fraction of US$ 11.02 for linear accelerators and US$ 4.87 for cobalt machines. These figures do not include the costs for physicians.
CONCLUSIONS: The variation of the costs per fraction is more due to the result of differences in machine usage and costs of equipment than of national economic status. A treatment fraction on a linac with functionality comparable to cobalt, costs 50% more than cobalt therapy. This project shows that it is possible to collect data on economic factors prospectively as well as retrospectively.

Entities:  

Mesh:

Year:  2004        PMID: 15172152     DOI: 10.1016/j.radonc.2004.02.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

Review 1.  Challenges and Prospects for Providing Radiation Oncology Services in Africa.

Authors:  Onyinye Balogun; Danielle Rodin; Wilfred Ngwa; Surbhi Grover; John Longo
Journal:  Semin Radiat Oncol       Date:  2016-11-24       Impact factor: 5.934

2.  Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency.

Authors:  Timothy P Hanna; Alfred C T Kangolle
Journal:  BMC Int Health Hum Rights       Date:  2010-10-13

3.  Global Access to Radiotherapy Services: Have We Made Progress During the Past Decade?

Authors:  Mei Ling Yap; Eduardo Zubizarreta; Freddie Bray; Jacques Ferlay; Michael Barton
Journal:  J Glob Oncol       Date:  2016-03-16

Review 4.  Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings.

Authors:  Emily S Wu; Jose Jeronimo; Sarah Feldman
Journal:  J Glob Oncol       Date:  2017-05-11

5.  Model for Estimating Power and Downtime Effects on Teletherapy Units in Low-Resource Settings.

Authors:  Rachel McCarroll; Bassem Youssef; Beth Beadle; Maureen Bojador; Rex Cardan; Robin Famiglietti; David Followill; Geoffrey Ibbott; Anuja Jhingran; Christoph Trauernicht; Peter Balter; Laurence Court
Journal:  J Glob Oncol       Date:  2017-01-11

6.  Automatic detection of graticule isocenter and scale from kV and MV images.

Authors:  Raymond Fang; Jinzhong Yang; Weiliang Du; Laurence Court
Journal:  J Appl Clin Med Phys       Date:  2019-03-06       Impact factor: 2.102

7.  Patterns of Care of Cancers and Radiotherapy in Ethiopia.

Authors:  Tara Rick; Biruk Habtamu; Wondemagegnhu Tigeneh; Aynalem Abreha; Yvette van Norden; Surbhi Grover; Mathewos Assefa; Luca Incrocci
Journal:  J Glob Oncol       Date:  2019-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.